Progress of protein and RNA in the diagnosis of early pancreatic cancer

Abstract

About 90% of pancreatic cancers originate from ductal adenocarcinoma of the ductal epithelium. The best treatment for this disease is surgical resection after early diagnosis. Due to lack of specific clinical symptoms in the early stage, most patients have entered the advanced stage after diagnosis, the tumor has undergone distant metastasis and can not perform radical surgery, and pancreatic cancer is not sensitive to radiotherapy and chemotherapy, so only palliative care can be chosen. Protein and RNA can be extracted and detected stably in tissues, excreta, serum, plasma, and can effectively reduce cost and technical difficulty. With the development of proteomics and RNAomics technology, more and more new tumor markers have been found. These new tumor markers can help to improve the early diagnosis rate of pancreatic cancer to a certain extent, thereby improving the radical surgery of pancreatic cancer patients. Resection rate improves patient prognosis. This article describes the biomarkers of pancreatic cancer in recent years from the study of protein and RNA levels. Key words: Pancreatic neoplasms; Tumor markers, biological; Early diagnosis; Proteinomics